---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-003473"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:28:29.204622+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma closes $5M private placement, issues shares and warrants

## Summary
- Issued 5,952,381 units at $0.84/unit; each unit = 1 share (or pre-funded warrant) + 2 warrants at $0.59 exercise price.
- Warrants to purchase up to 11,904,762 shares, exercisable at $0.59 per share, term 5.5 years from issuance.
- Aegis Capital Corp. received 10% of gross proceeds as placement agent fee, plus 2% non-accountable expense allowance.
- Company obligated to file resale registration statement with SEC within 15 days; liquidated damages for delay.
- Private placement closed on May 16, 2023 with a single healthcare-focused institutional investor.

## SEC filing metadata
- accession: 0001683168-23-003473
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823003473/0001683168-23-003473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823003473/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-003473
- JSON: https://secwatch.observer/filing/0001683168-23-003473.json
- Plain text: https://secwatch.observer/filing/0001683168-23-003473.txt

## Key facts
- Material Agreements
  Sunshine Biopharma Inc. entered into Placement Agent Agreement with Aegis Capital Corp. valued at Commission of 10% of gross proceeds, 2% expense allowance, and 10% of proceeds from warrant exercise (effective 2023-05-12).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Aegis Capital Corp.
  - Value: Commission of 10% of gross proceeds, 2% expense allowance, and 10% of proceeds from warrant exercise
  - Effective: 2023-05-12
  source text: Aegis Capital Corp. (“Aegis”) acted as the placement agent in connection with the Private Placement. Pursuant to the placement agent agreement between the Company and Aegis (the “Placement Agent Agreement”), Aegis was paid a commission equal to 10% of the gross proceeds received by the Company in the Private Placement, and a non-accountable expense allowance equal to 2% of the gross proceeds, and will receive 10% of the proceeds from any exercise of Investor Warrants, payable on exercise.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823003473/0001683168-23-003473-index.htm
- Material Agreements
  Sunshine Biopharma Inc. entered into Securities Purchase Agreement with accredited and institutional investor valued at Private placement of common stock, pre-funded warrants, and investor warrants for gross proceeds of (effective 2023-05-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: accredited and institutional investor
  - Value: Private placement of common stock, pre-funded warrants, and investor warrants for gross proceeds of
  - Effective: 2023-05-12
  source text: On May 12, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain accredited and institutional investor for a private placement (“Private Placement”) for the Company’s common stock, pre-funded warrants, each exercisable to purchase one share of common stock (“Pre-Funded Warrants”), and warrants, each exercisable to purchase one share of common stock (“Investor Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823003473/0001683168-23-003473-index.htm
- Material Agreements
  Sunshine Biopharma Inc. entered into Registration Rights Agreement with accredited and institutional investor valued at Agreement to file a resale registration statement within 15 days of closing, with potential liquidat (effective 2023-05-12).
  - Action: entry
  - Counterparty: accredited and institutional investor
  - Value: Agreement to file a resale registration statement within 15 days of closing, with potential liquidat
  - Effective: 2023-05-12
  source text: In connection with the Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the investor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823003473/0001683168-23-003473-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.